{"id":"agls","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL2218927","moleculeType":"Small molecule","molecularWeight":"280.36"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AGLS reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"AGLS is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:17.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05503953","phase":"PHASE3","title":"Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS","status":"UNKNOWN","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2022-09-05","conditions":"Essential Hypertension","enrollment":306},{"nctId":"NCT04686643","phase":"PHASE3","title":"Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension","status":"UNKNOWN","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2021-02-01","conditions":"Hypertension","enrollment":306}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["S-amlodipine, Valsartan"],"phase":"phase_3","status":"active","brandName":"AGLS","genericName":"AGLS","companyName":"Ahn-Gook Pharmaceuticals Co.,Ltd","companyId":"ahn-gook-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGLS is a small molecule that targets the SGLT2 receptor. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}